EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients

Ingrid A Franken, Steven L C Ketelaars, Carmen Rubio-Alarcón, Pien Delis-van Diemen, Tessa O M Spaapen, Floor Heilijgers, Marcos da Silva Guimaraes, Sietske C M W van Nassau, Suzanna J Schraa, Wilma E Mesker, Wendy W J de Leng, Onno Kranenburg and 8 more

European Journal of Cancer · 2026-03 · 236 · 116262

DOI: 10.1016/j.ejca.2026.116262 ↗

At a glance

Journal article in European Journal of Cancer, 2026-03. Written by Ingrid A Franken and 19 co-authors. Institution: Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands. Major MEDLINE topics: Smad4 Protein, Colonic Neoplasms, Mutation, Drug Resistance, Neoplasm. Cited 2 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY 4.0). Funded by: Stand up to Cancer, Health~Holland, KWF Kankerbestrijding.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

INTRODUCTION: Stage III colon cancer (CC) is routinely treated with resection followed by adjuvant chemotherapy (ACT). However, 50 % of patients are cured by surgical intervention alone, whilst another 30 % experience disease recurrence despite ACT. This study aimed to identify biomarkers prognostic of recurrence and/or predictive of response to ACT. MATERIALS AND METHODS: Prognostic value of clinicopathological features, transcriptional profiles and genomic mutations was examined for patients with microsatellite stable (MSS) and instable (MSI) CC receiving ACT, as well as in a sub-cohort of patients with minimal residual disease (MSS-MRD) detected by post-surgery circulating tumour DNA. RESULTS: In MSS patients (N = 199), recurrence was associated with pT4 and/or pN2 tumours (HR 3.5 [2.0-5.9], p < 0.001); CMS4 (HR 2.6 [1.2-5.4], p = 0.008); a high cancer-associated fibroblast (CAF) signature (HR 2.2 [1.4-3.6], p = 0.001); and SMAD4 mutations (HR 2.1 [1.1-4.2], p = 0.027). In the MSS-MRD sub-cohort (N = 23), lack of response to ACT was associated with a high CAF-signature (HR 5.3 [1.7-17], p = 0.002) and SMAD4 mutations (HR 3.4 [0.9-13], p = 0.060). DISCUSSION: A high CAF-signature and SMAD4 mutations have prognostic value for recurrence both in MSS CC and in MRD, indicating potential predictive value for response to ACT. This molecular profile provides leads to design novel therapies for patients resistant to standard ACT.

Subjects

MeSH terms (MEDLINE)

Smad4 ProteinColonic NeoplasmsMutationDrug Resistance, NeoplasmCancer-Associated FibroblastsBiomarkers, TumorHumansChemotherapy, AdjuvantFemaleMaleNeoplasm StagingAgedMiddle AgedNeoplasm Recurrence, LocalMicrosatellite InstabilityNeoplasm, ResidualPrognosisAdultAged, 80 and overCirculating Tumor DNA

Author keywords

Adjuvant chemotherapyCancer-associated fibroblastsCirculating tumour DNAColon cancerSMAD4 mutation

Substances

Smad4 ProteinSMAD4 protein, humanBiomarkers, TumorCirculating Tumor DNA

Authors and institutions

  • Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Laboratory of Translational Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Department of Surgery, Leiden University Medical Centre, the Netherlands.
  • Department of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands.
  • Labcorp Oncology, Baltimore, MD, USA.

Funding

  • Stand up to Cancer
  • Health~Holland
  • KWF Kankerbestrijding
  • Maag Lever Darm Stichting

Cite

APA

Franken, I. A., Ketelaars, S. L. C., Rubio-Alarcón, C., Delis-van Diemen, P., Spaapen, T. O. M., Heilijgers, F., da Silva Guimaraes, M., van Nassau, S. C. M. W., Schraa, S. J., Mesker, W. E., de Leng, W. W. J., Kranenburg, O., Meijer, G. A., Koopman, M., Sausen, M., Vink, G. R., Abeln, S., Fijneman, R. J. A., Roodhart, J. M. L., & PLCRC-MEDOCC group (2026). Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients. European Journal of Cancer, 236, 116262. https://doi.org/10.1016/j.ejca.2026.116262

Vancouver

Franken IA, Ketelaars SLC, Rubio-Alarcón C, Delis-van Diemen P, Spaapen TOM, Heilijgers F, et al. Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients. European Journal of Cancer. 2026;236:116262. doi:10.1016/j.ejca.2026.116262

BibTeX
@article{Franken2026,
  author = {Franken, Ingrid A and Ketelaars, Steven L C and Rubio-Alarcón, Carmen and Delis-van Diemen, Pien and Spaapen, Tessa O M and Heilijgers, Floor and da Silva Guimaraes, Marcos and van Nassau, Sietske C M W and Schraa, Suzanna J and Mesker, Wilma E and de Leng, Wendy W J and Kranenburg, Onno and Meijer, Gerrit A and Koopman, Miriam and Sausen, Mark and Vink, Geraldine R and Abeln, Sanne and Fijneman, Remond J A and Roodhart, Jeanine M L and PLCRC-MEDOCC group, PLCRC-MEDOCC group},
  title = {Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {236},
  pages = {116262},
  doi = {10.1016/j.ejca.2026.116262}
}
Start for free →